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Abstract. Multi-disciplinary research has revealed evidence of significant abnormality in a much wider range and level of
information processing than that currently definitive for amnestic mild cognitive impairment (MCI). This raises the possibility
that the contemporary approach to MCI is inappropriately delimited, and the true nature and extent of brain dysfunction and thus
disease burden, underestimated. It follows therefore that the closely related concept of subjective cognitive impairment (SCI)
may be similarly constrained. Although research into the wider range of potential brain dysfunction in MCI and SCI is in its
infancy, as yet precluding systematic reviews, we present here findings to prompt debate about SCI with respect to its clinical
assessment and its personal and societal burden.
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INTRODUCTION
Subjective cognitive impairment (SCI) is a disorder
in which ostensibly healthy individuals report self-
perceived impairment in cognition, usually memory,
in the absence of objective evidence on formal neu-
ropsychological assessment [1]. Historically, given the
existence of both subjective memory complaints and
impaired episodic memory in mild cognitive impair-
ment (MCI), an earlier clinical stage, where subjective
memory complaints exist in the absence of detectable
objective cognitive deficits, was proposed by Reisberg
(see Rodda et al. [2] and Reisberg et al. [3]). Indeed,
what is commonly termed SCI is evidence of this.
∗Correspondence to: Andrea Tales, College of Human and
Health Sciences, Department of Psychology, Swansea University,
Swansea, Wales, UK. Tel.: +44 1792 205678; E-mail: A.Tales@
swansea.ac.uk.
Although the etiology of SCI is heterogeneous, being
associated with increasing age [4], depression [5–8],
numerous medical illnesses, and various medications
[9], there is growing evidence that SCI is associated
with increased risk of developing AD [1, 9–12] and
of brain changes characteristic of Alzheimer’s disease
(AD) [2, 13]. These findings lead to the conclusion
that SCI is increasingly recognized as a precursor to
the earliest stages of AD with a subgroup of patients
who will ultimately progress to develop neuropsycho-
logical declines consistent with MCI or AD. There are
several advantages to studying SCI as if it were a pre-
clinical stage of AD. For example, a pre-MCI stage of
a dementing process when patients have more intact
cognitive abilities may be more likely to be responsive
to treatment than MCI.
Traditionally, preclinical and clinical AD are defined
based on objective, standardized, neuropsychological
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assessments. Compared to cognitively healthy aging,
MCI is associated with an increased risk of developing
AD, especially in the presence of positive biomarker
evidence. Thus for some individuals, it represents a
point along a cognitive continuum ranging from nor-
mality to AD. Not surprisingly, therefore, MCI is a
concept and diagnosis derived primarily from, and
defined by, measures used to characterize and diagnose
AD. Furthermore, the dominant clinical and research
priorities for MCI relate to its potential for conver-
sion to AD, the identification of early disease markers,
and the development of interventional and preven-
tative schemes to ameliorate personal, societal, and
economic-related disease burden.
Defining and diagnosing MCI in terms of acquired
impairment in neuropsychological measures of high-
level processes such as memory, cognition, language,
executive function, and perception (namely those tests
used in the diagnosis and definition of AD) has ensured
clinical continuity between the two disease entities,
and helped establish the link between them. However,
such tests tend to be relatively insensitive to the very
early stage of disease i.e., in predicting for whom MCI
represents prodromal AD. Furthermore, this strategy
fails to recognize the potential for breakdown in the
integrity of a much wider range of brain functions and
in lower or more fundamental levels of information
processing with respect to the diagnosis, manage-
ment, and characterization of MCI, despite emerging
research evidence to the contrary. The approach arises
perhaps from enduring tacit assumptions that the symp-
toms of AD (and therefore of MCI) result primarily
from the disruption of high level (e.g., cortico-cortical)
functions and that if these are preserved then so too are
more fundamental levels; and that lower level deficits
per se do not influence behavior. Arguably, therefore,
the original approach to the concept and diagnosis
of MCI may have led to its incomplete characteriza-
tion and underestimation of both individual and social
burden. Recent evidence indicates that functional dis-
ruption in MCI at group level can be associated with
the presence of amnestic deficit per se, or specific to
the presence of prodromal dementia [14, 15]. Thus the
priority given to determining early markers of AD
in patients with MCI obscures the fact that individ-
uals with MCI, irrespective of whether or not they
develop dementia, may experience a far greater burden
of deficits than initially recognized.
We propose that SCI may be associated with dys-
function of a wide range and level of brain functions,
just as is found in MCI. By continuing to adopt the
traditional clinical and research approach to SCI, we
are potentially omitting information not only relevant
to the relationship between SCI, MCI, and dementia,
but also apposite to our understanding of its signs and
symptoms and its effect upon environmental interac-
tion and interpretation, and thus its associated burden
on behavior and everyday life. Furthermore, for some
individuals with SCI the absence of objective cogni-
tive dysfunction arises simply from the insensitivity of
the choice of cognitive test. Evaluating the functional
integrity of other aspects and levels of brain function
in SCI may reveal subtle associated or even causal
changes that are not apparent from neuropsychological
testing.
To illustrate these points, the following overview
of research-evinced dysfunction in MCI, although not
exhaustive or accompanied by meta-analysis, is pre-
sented in order to provoke discussion on whether an
immediate broader approach to SCI is indicated. As
the typical deficit in MCI is in the domain of mem-
ory, most studies (such as those described below) have
involved participants with amnestic MCI; however, it is
important to also acknowledge the existence of forms
of MCI in which multiple and various other cogni-
tive domains can be affected, again in the absence of
significant disability.
ADDITIONAL DEFICITS IN AMNESTIC
MCI
Increasingly apparent is the basis for potential
abnormality in an extensive array of fundamental
information-processing in MCI compared to cog-
nitively healthy aging. These abnormalities include
objectively ascertained disruption to brain physiology,
structural and functional integrity, connectivity, the
neural synchronization of cortical networks, physio-
logical reactivity, white matter integrity, the default
mode network, and the intra-individual variability
of processing speed [14, 16–27]. More specifically,
impaired visual and visual attention-related processing
over a wide range of component operations and lev-
els, including early pre-attentive and later perceptual,
is an increasingly common finding in MCI compared
to cognitively healthy aging [26, 28, 29–35]. Addi-
tional abnormalities include the more rapid decay
of visual sensory (iconic) memory [36], abnormali-
ties in pre-attentive change detection and processing
[30, 37, 38], motion processing [29, 39, 40], contrast
sensitivity function [41], eye movements [42, 43], pha-
sic alerting [14, 44], visuospatial function [45–48],
visual search [26, 49], visuospatial perception [50];
attentional control, selective and focused attention [35,
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51, 52], the selective inhibition of irrelevant informa-
tion processing, i.e., cross-modal inhibition [53], and
increased perceptual thresholds [30]. However, out-
come may depend upon the type of MCI measured
and the methodology used [26, 46, 48], and it is pos-
sible also that some contribution to these results arises
from patients in the early stages of visual variants of
AD. Nevertheless, similar dysfunction in visual and
attention-related processing is seen in typical AD [54].
Although less commonly measured than visual and
attention-related information processing, significant
disruption to central auditory processing [55], olfaction
[56], taste [57], and somatosensory function [58, 59],
together with abnormal multisensory integration [60],
cortico-cortical processing [17] and sensory-motor
function [61], sleep abnormality [62], and autonomic
dysfunction [63], are also apparent in MCI compared
to cognitively healthy aging.
As such processes are fundamental requirements for
environmental awareness, interaction, interpretation,
response, and thus everyday behavior, degradation
within these and associated operational networks have
the potential for significant negative impact. They are
likely also to contribute to, or exacerbate, the char-
acteristic decline in higher level cognitive function in
MCI [64–66] and explain the reports of impairments
in driving, increased risk of poor balance and falls and
difficulties with other instrumental activities of daily
living [67–70]. Such abnormality in a range of fun-
damental operations should alert us to the possibility
that AD-related treatments and interventions should
not simply be aimed at high-level functions such as
memory, cognition, and perception. These results also
indicate that, as SCI can represent a pre-MCI/AD stage,
it may also be associated with a similar wide range
of dysfunction. Indeed, as described below, emerging
evidence indicates that this is so.
SCI: ADDITIONAL ABNORMALITIES
BEYOND NEUROPSYCHOLOGICAL
DEFICITS
Associations between SCI and direct measures of
underlying brain changes are emerging. There is evi-
dence of objective SCI-related changes in fundamental
processing, e.g., default-mode network disruption
[71], alterations in brain neural synchronization and
function [13, 18, 72], changes in white [73] and gray
matter [74], volumetric and metabolic changes [2,
75], and change in visual contrast sensitivity function
[41] and divided attention [2]. Thus readily measur-
able abnormality in the functional integrity of a range
and level of processing occurs in SCI independently
of what appears to be objectively normal cognitive
processing. This may contribute to the self-reports
of memory changes even if neuropsychological test
results are ‘normal’.
Despite such research-related findings in MCI and
SCI (and indeed in AD), the potential for abnormal-
ity in such a wide range and level of brain function is
not taken into account or addressed in the new propos-
als for the diagnostic criteria for MCI or SCI aimed
at promoting earlier detection [77]. Similarly, whereas
the importance of cognitive decline is recognized in the
English National Dementia Strategy ([77], and see also
[78–82]), the potential for and impact of a wider range
of deficits is not, despite their potential to influence
behavior, disease burden, fitness to work, frailty, social
isolation, coping strategies, social exclusion, loss of
independence, and the provision of appropriate care.
Neither are they recognized with respect to the devel-
opment of early disease markers, or the development
of disease interventions, or the measurement and inter-
pretation of their efficacy. Furthermore, as SCI per se
has for many people both functional and emotional
significance, extending diagnostic testing could also
help in determining for whom SCI and MCI is not
related to early AD. In addition, such investigation
has the potential to highlight deficits in processing that
may adversely affect behavior and quality of life and
increase disease burden, irrespective of whether SCI
signals pre-dementia or not.
Another factor influencing the early diagnosis of
dementia in MCI and SCI is that cognitive function
may be maintained, namely performance on stan-
dard neuropsychological measures may be within the
normal range despite underlying pathology, due to cog-
nitive reserve and re-organizational and compensatory
strategies [83, 84]. By limiting the investigation of cog-
nitive reserve to high-level cognitive function (i.e., with
respect to the same neuropsychological tests used in the
diagnosis of AD), we are limiting our potential to fully
understand its basis and to find new ways of identify-
ing early signs of significant disease in those with high
reserve.
ACTION
Arguably, as the potential benefits of intervention
and treatment of pre-dementia AD are recognized, the
evidence presented here indicates that the concept of,
and clinical and research approach to SCI should be
expanded by an immediate strategy of testing a wider
range of brain function in both clinical practice and
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research. More specifically, such a strategy is likely
to benefit the individual and society with respect to
an increased awareness and understanding of SCI and
the range of brain functions that may be detrimentally
affected and their consequence for behavior, irrespec-
tive of whether they are specific to the presence of
neurodegenerative change. Against such an approach
is the fact that currently there are no proven effective
disease modifying treatments for AD irrespective of its
stage (i.e., SCI and MCI). Thus the benefit to the indi-
vidual or society in striving for increased knowledge
in this area and the substantial economic cost of such
research and the development of new tests can be ques-
tioned. Nevertheless, arguably the more we learn about
SCI and indeed MCI and AD, the greater the potential
to reduce the economic burden of these conditions,
even in the current absence of successful interven-
tion (e.g., see Lin and Neuman [85]). Furthermore, the
majority of research studies examining brain function
in MCI and SCI have been cross-sectional in nature.
This paucity of longitudinal studies renders it difficult
to determine whether abnormality in the novel aspects
of information processing in MCI or SCI described
above, results from the disproportionately poorer per-
formance of those patients for whom MCI or SCI
represents pre-dementia, or whether it more generally
accompanies amnestic or cognitive dysfunction per se.
Similarly, longitudinal study of SCI performance on
established neuropsychological tests are essential in
order to discriminate whether a score that is outside
the normative range represents an early stage of decline
from a premorbid level or a lifelong and stable indi-
vidual difference.
Study replication levels are also low which precludes
the performance of meta-analysis and thus associated
measures of validity, reliability, and specificity. The
evidence presented emphasizes the need for a longitu-
dinal approach.
We therefore invite debate with respect to whether
the current approach to SCI should be changed imme-
diately in response to growing research evidence
suggesting a much wider range and level of brain dys-
function in MCI and AD than had previously been
recognized. Alternatively, should we await the out-
come of additional longitudinal studies before making
such a decision—or is there no need for our approach
to SCI to change at all?
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